Skip to main content
Evidence Snapshot

Xenopus laevis

CHEMBL613478 ORGANISM Xenopus laevis
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:09Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613478
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Xenopus laevis as ChEMBL target CHEMBL613478. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Xenopus laevis
ORGANISM · Xenopus laevis
As of 2026-09-13
ChEMBL target ID
CHEMBL613478
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Xenopus laevis matters

As of 2026-09-13

Xenopus laevis is reviewed as Xenopus laevis; the current evidence base includes 4 approved drugs, 195 compounds, and 65 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 195 compounds, and 65 assays for this target. The dominant activity type is EC50. CHEMBL2314253 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL2314253 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Xenopus laevis matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

195
Total Compounds
65
Total Assays
4
Approved Drugs
EC50: 146.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2314253
 11.0 EC50 —
No preferred name
CHEMBL2314255
 10.5 EC50 —
No preferred name
CHEMBL10878
 9.5 EC50 Approved
No preferred name
CHEMBL290895
 8.6 EC50 —
No preferred name
CHEMBL15013
 7.3 EC50 —

Approved Drugs

Structure Compound First Approval
BREXANOLONE
CHEMBL207538
 2019
AGOMELATINE
CHEMBL10878
 2009
PROPOFOL
CHEMBL526
 1989
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:09Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613478